Goldman Sachs Group Inc Monte Rosa Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $596 Billion
  • Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 356,112 shares of GLUE stock, worth $1.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
356,112
Previous 356,112 -0.0%
Holding current value
$1.65 Million
Previous $1.65 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025
BUY
$4.64 - $7.17 $910,544 - $1.41 Million
196,238 Added 122.75%
356,112 $1.65 Million
Q4 2024

Feb 11, 2025
SELL
$4.8 - $10.36 $89,908 - $194,053
-18,731 Reduced 10.49%
159,874 $1.11 Million
Q3 2024

Nov 14, 2024
BUY
$3.59 - $6.97 $309,659 - $601,204
86,256 Added 93.4%
178,605 $946,000
Q2 2024

Aug 13, 2024
BUY
$3.38 - $7.86 $258,857 - $601,958
76,585 Added 485.82%
92,349 $345,000
Q1 2024

May 15, 2024
SELL
$4.26 - $8.46 $91,223 - $181,162
-21,414 Reduced 57.6%
15,764 $111,000
Q4 2023

Feb 13, 2024
SELL
$2.5 - $5.93 $42,580 - $100,999
-17,032 Reduced 31.42%
37,178 $210,000
Q3 2023

May 14, 2024
BUY
$4.78 - $7.22 $81,412 - $122,971
17,032 Added 45.81%
54,210 $259,000
Q3 2023

Nov 14, 2023
BUY
$4.78 - $7.22 $42,417 - $64,070
8,874 Added 19.57%
54,210 $259,000
Q2 2023

May 14, 2024
BUY
$4.53 - $8.4 $59,356 - $110,065
13,103 Added 40.65%
45,336 $310,000
Q2 2023

Aug 14, 2023
BUY
$4.53 - $8.4 $59,356 - $110,065
13,103 Added 40.65%
45,336 $310,000
Q1 2023

May 14, 2024
SELL
$5.95 - $8.21 $69,787 - $96,295
-11,729 Reduced 26.68%
32,233 $251,000
Q1 2023

May 11, 2023
SELL
$5.95 - $8.21 $69,787 - $96,295
-11,729 Reduced 26.68%
32,233 $251,000
Q4 2022

May 14, 2024
BUY
$6.71 - $9.72 $71,582 - $103,692
10,668 Added 32.04%
43,962 $334,000
Q4 2022

Feb 13, 2023
BUY
$6.71 - $9.72 $71,582 - $103,692
10,668 Added 32.04%
43,962 $334,000
Q3 2022

May 14, 2024
SELL
$7.17 - $12.16 $48,913 - $82,955
-6,822 Reduced 17.01%
33,294 $272,000
Q3 2022

Nov 10, 2022
SELL
$7.17 - $12.16 $48,913 - $82,955
-6,822 Reduced 17.01%
33,294 $272,000
Q2 2022

May 14, 2024
BUY
$6.15 - $14.99 $18,068 - $44,040
2,938 Added 7.9%
40,116 $388,000
Q2 2022

Aug 15, 2022
SELL
$6.15 - $14.99 $59,661 - $145,417
-9,701 Reduced 19.47%
40,116 $388,000
Q1 2022

May 16, 2022
BUY
$10.36 - $20.41 $156,135 - $307,599
15,071 Added 43.37%
49,817 $698,000
Q4 2021

Feb 14, 2022
BUY
$16.28 - $27.15 $254,407 - $424,273
15,627 Added 81.74%
34,746 $710,000
Q3 2021

Nov 10, 2021
BUY
$18.59 - $42.21 $355,422 - $807,012
19,119 New
19,119 $426,000

Others Institutions Holding GLUE

# of Institutions
107
Shares Held
53.4M
Call Options Held
69.1K
Put Options Held
22.4K
View Full List

About Monte Rosa Therapeutics, Inc.

GLUE Quotes by TradingView
  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $216M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email